Written by the Nuvirox Research Team
Key points
- Rapamycin extends lifespan in mice more reliably than almost any other compound. It has never been shown to extend lifespan in humans, and no trial currently underway is designed to answer that question.
- The first long randomized human healthspan trial (PEARL, 48 weeks, 114 completers) found no excess serious adverse events and modest, sex-specific body-composition changes — not the broad rejuvenation the popular coverage implied.
- Rapamycin is a prescription immunosuppressant. Off-label longevity use is a genuine medical decision that belongs with a physician, not a podcast.
Short answer: the animal evidence is exceptional, the human evidence is early and much narrower, and the honest position is uncertainty. Rapamycin (sirolimus) inhibits mTORC1, and lowering mTORC1 signalling extends lifespan in yeast, worms, flies, and mice — in mice, even when started in middle age. That is a remarkable finding and the reason a serious research community exists around this drug. But the first long randomized trial in healthy humans reported a much more limited set of changes, used a formulation the investigators later discovered was poorly absorbed, and measured body-composition surrogates rather than disease or death. Anyone who tells you the question is settled in either direction is ahead of the data.
Design and reported outcomes of the PEARL trial (NCT04488601), the longest randomized trial of rapamycin for healthy ageing published to date.
What does rapamycin actually do?
Rapamycin binds an intracellular protein called FKBP12, and that complex then inhibits mTORC1. As we describe in our explainer on what the mTOR pathway does, mTORC1 is the switch that decides whether a cell builds or recycles. Inhibiting it shifts cells toward autophagy and away from protein synthesis and proliferation.
That mechanism is why the drug was originally developed as an immunosuppressant for organ transplant recipients: lymphocytes proliferate to mount an immune response, and blocking mTORC1 blunts that proliferation. It is also used in certain cancers and on drug-eluting coronary stents. Those are its approved uses. Longevity use is off-label and involves different, much lower, intermittent dosing.
Why the mouse data is genuinely impressive
Rapamycin has extended median and maximum lifespan in genetically heterogeneous mice across multiple independent laboratories, including when treatment began at 20 months of age — roughly equivalent to a human in their sixties. Reproducibility across sites and late-life initiation are both unusual and both count in the drug’s favour.
There is also mechanistically coherent supporting work. Joseph and colleagues found that partial mTORC1 inhibition in aged rats counteracted the decline in muscle mass and reversed sarcopenia-associated molecular signalling — which matters because the obvious worry about an anti-growth drug is that it would accelerate muscle loss.
What human studies actually show
PEARL: 48 weeks, 114 completers, modest findings. The Participatory Evaluation of Aging with Rapamycin for Longevity trial randomised healthy adults aged 50 to 85 to placebo, 5 mg per week, or 10 mg per week of compounded rapamycin. Of the 114 who completed, 39 received placebo, 40 received 5 mg, and 35 received 10 mg. The primary outcome was visceral fat measured by DXA. Investigators reported no significant differences in safety blood biomarkers or moderate-to-severe adverse events versus placebo, alongside sex-specific gains — lean tissue mass in women at the higher dose, bone mineral content in men.
Study snapshot — PEARL
| Design | Decentralised, double-blind, randomized, placebo-controlled |
| Participants | 114 completers, healthy, aged 50–85 |
| Dose | 5 mg or 10 mg compounded rapamycin weekly, or placebo |
| Duration | 48 weeks |
| Primary outcome | Visceral adipose tissue by DXA |
| Registration | NCT04488601 |
The honest counterweight the authors raised themselves. Mid-trial, the investigators discovered that the compounded rapamycin they used was substantially less bioavailable than commercially manufactured sirolimus. That means participants likely received considerably less active drug than the nominal 5 and 10 mg figures suggest. This cuts both ways: it weakens confidence in the efficacy signals, and it also means the reassuring safety profile was established at a lower effective exposure than the labels imply. Neither interpretation is flattering to a confident conclusion.
The best human functional result is not from rapamycin itself. Mannick and colleagues used the analogue RAD001 (everolimus) in 159 adults aged 65 and over for six weeks before influenza vaccination and found roughly a 20% improvement in antibody response compared with 59 controls. This is a real, functional, age-related outcome. It is also a six-week immune endpoint, not evidence about ageing broadly.
What rapamycin will not do, and what it might cost
It will not make you live longer on any evidence currently in existence. No human trial has measured lifespan, and none is running. Extrapolating from mice to a 40-year human outcome is an assumption, not a finding.
It is not side-effect free. In transplant doses, rapamycin causes mouth ulcers, impaired wound healing, raised triglycerides and cholesterol, glucose intolerance, and increased infection risk. Intermittent low doses are intended to reduce these, and PEARL did not detect an excess of serious events — but 114 people over 48 weeks cannot rule out uncommon harms, and the bioavailability problem complicates even that reassurance.
It is a prescription drug obtained, in the longevity context, through off-label prescribing or compounding pharmacies of variable quality. If you are considering it, that is a conversation for a physician who can review your medication list, infection risk, surgical plans, and metabolic bloodwork. Please do not treat this article as a recommendation in either direction — it is a summary of what has and has not been shown.
What the more accessible interventions look like
If the appeal of rapamycin is the underlying idea — periodically lowering growth signalling to permit cellular housekeeping — then the interventions with fewer unknowns are energy restriction and exercise. The CALERIE trial of sustained calorie restriction is the closest thing to a randomized human geroscience trial that exists, and its effect was small but measurable. That is a more defensible starting point than a compounded immunosuppressant.
It is also worth being clear about what rapamycin does not touch. It does not raise NAD+, it does not clear senescent cells, and it does not address the specific mechanisms those other branches of ageing research target. The geroscience field is not a single lever.
Frequently asked questions
Is rapamycin safe to take for longevity?
Nobody can honestly answer that yet. The one long randomized trial in healthy adults found no excess serious adverse events over 48 weeks, at an exposure that was probably lower than intended, in 114 people. That is genuine information and it is not a safety guarantee over years or decades.
What dose do longevity users take?
The doses tested in PEARL were 5 mg and 10 mg weekly, which reflects what is commonly used off-label and is far below the daily immunosuppressive dosing used in transplantation. We are describing what was studied, not recommending a regimen.
Can I get a similar effect from fasting?
Fasting lowers mTORC1 signalling through the same nutrient-sensing inputs, so the direction is comparable. The magnitude and duration of suppression are not, and no study has compared them head to head on any meaningful outcome.
Does rapamycin cause muscle loss?
The intuitive worry is reasonable, but the rodent work on partial mTORC1 inhibition found preserved muscle mass, and PEARL reported lean tissue gains rather than losses in women at the higher dose. The picture is more favourable than the mechanism alone would predict.
Is this the same as taking an NAD+ precursor?
No. They act on entirely different pathways. NAD+ precursors support the cofactor pool that sirtuins and DNA-repair enzymes draw on; rapamycin inhibits a growth-signalling kinase.
From Nuvirox
Why we formulated NAD+ Restore
- 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Rapamycin is the most compelling longevity compound in animals and one of the least resolved in humans. The first long randomized trial in healthy adults is a real contribution and a modest one: reassuring on short-term safety, suggestive on body composition, silent on everything people actually hope for, and complicated by a bioavailability problem the investigators disclosed honestly. The fair reading is that this is a live research question deserving better trials, not a settled protocol.
References
- Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025. DOI: 10.18632/aging.206235. PMCID: PMC12074816. ClinicalTrials.gov: NCT04488601
- Harinath G, Lee V, Nyquist A, et al. Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL trial results. medRxiv preprint. 2024. DOI: 10.1101/2024.08.21.24312372
- Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6(268):268ra179. DOI: 10.1126/scitranslmed.3009892
- Joseph GA, Wang SX, Jacobs CE, et al. Partial inhibition of mTORC1 in aged rats counteracts the decline in muscle mass and reverses molecular signaling associated with sarcopenia. Molecular and Cellular Biology. 2019;39(19):e00141-19. DOI: 10.1128/MCB.00141-19. PMID: 31308131. PMCID: PMC6751631
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.